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Abstract
Background: Evaluation of company clinical trial reports could provide information for meta-
analysis at the commercial introduction of a new technology.
Methods: Clinical trial reports of sildenafil for erectile dysfunction from September 1997 were
used for meta-analysis of randomised trials (at least four weeks duration) and using fixed or dose
optimisation regimens. The main outcome sought was an erection, sufficiently rigid for penetration,
followed by successful intercourse, and conducted at home.
Results: Ten randomised controlled trials fulfilled the inclusion criteria (2123 men given sildenafil
and 1131 placebo). NNT or NNH were calculated for important efficacy, adverse event and
discontinuation outcomes. Dose optimisation led to at least 60% of attempts at sexual intercourse
being successful in 49% of men, compared with 11% with placebo; the NNT was 2.7 (95%
confidence interval 2.3 to 3.3). For global improvement in erections the NNT was 1.7 (1.6 to 1.9).
Treatment-related adverse events occurred in 30% of men on dose optimised sildenafil compared
with 11% on placebo; the NNH was 5.4 (4.3 to 7.3). All cause discontinuations were less frequent
with sildenafil (10%) than with placebo (20%). Sildenafil dose optimisation gave efficacy equivalent
to the highest fixed doses, and adverse events equivalent to the lowest fixed doses.
Conclusion: This review of clinical trial reports available at the time of licensing agreed with later
reviews that had many more trials and patients. Making reports submitted for marketing approval
available publicly would provide better information when it was most needed, and would improve
evidence-based introduction of new technologies.
Background
Meta-analyses that include otherwise unpublished ran-
domised trials are uncommon [1], but are welcome, and
can inform in circumstances where information is contra-
dictory. The example of tramadol in acute pain, where in-
formation on 3,500 patients was made available,
explained the results of two studies, one showing that tra-
madol was a highly efficacious analgesic [2], the other
showing it to be no different from placebo [3]. The truth
was somewhere between. Despite the fact that tramadol
had been in common use in some European countries for
many years, fulfilling regulatory requirements for the
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United States required studies to be conducted to contem-
porary requirements, and meta-analysis brought useful re-
sults to light.
Meta-analysis of randomised studies before a new tech-
nology has become commercially available is even more
rare, though there is at least two examples [4,5]. Meta-
analyses are usually performed some years after first com-
mercial availability because the publication of ran-
domised trials performed for efficacy and/or safety
reasons takes time. The importance of meta-analysis in
drug development and regulatory procedures is increas-
ingly recognised [5,6].
The results of meta-analysis are undoubtedly important,
both in the regulatory process and for evaluation of rare
but serious adverse events. For COX-2 inhibitors meta-
analysis was being planned before the randomised trials
in order to examine the relationship between treatments
and rare events [5,6].
The point of greatest change, though, is in the period im-
mediately after commercial introduction. Media interest
can raise patient expectations at a time where healthcare
professionals and organisations have least knowledge and
experience, and when few have had the opportunity to
consider the full implications of the new technology on
budgets and services. For sildenafil, for instance, 85% of
first time prescriptions occurred in the first 12 weeks of
availability in one New England healthcare provider [7].
It is at this point, the point of marketing approval, when
there is the greatest need for the best information. At best
only a small number of trials may have been published,
and though they can be large, and usually are powered to
detect a difference from placebo or common current prac-
tice, they are unlikely to be able to measure accurately the
size of the benefit.
We sought to assess whether clinical trial reports present-
ed for marketing approval would provide the basis for a
systematic review at the time of launch if they were pub-
licly available. We did this with reference to the erectile
dysfunction treatment sildenafil (Viagra), using clinical
trial reports made available by Pfizer Ltd.
Methods
No search strategy was required because this review was of
material made available by Pfizer UK Ltd in the form of
clinical trial reports used in a marketing authorisation ap-
plication for sildenafil (Viagra) in September 1997. QUO-
RUM guidelines were otherwise followed [7]. The prior
intention was to use studies that were relevant to the use
of sildenafil in clinical practice. This required the setting
to be the home, not the clinic, use of sildenafil as required,
rather than fixed dosing schedules (such as daily tablets),
and studies of a minimum duration, which we set arbitrar-
ily as four weeks.
Excluded were studies with laboratory measures of penile
tumescence or rigidity with single doses of sildenafil, stud-
ies that only investigated erectile function in a clinic set-
ting, studies that used fixed daily dosing rather than as
required, and studies that were shorter than four weeks.
Included were randomised trials that investigated sildena-
fil, with efficacy or safety data, were longer than four
weeks, conducted in the home setting, and with doses in
the licensed range of 25 mg to 100 mg as required, al-
though lower and higher doses would be analysed if there
were sufficient information. Clinical trials in men with
erectile dysfunction caused specifically by single causes
like spinal cord trauma or diabetes were not included be-
cause, taken with the other data, they would constitute
clinical heterogeneity.
Each report was scored for quality using a three item, 1–5
score, quality scale [8]. Points were awarded to studies ac-
cording to whether they were randomised and double
blind and mentioned withdrawals or drop-outs from the
study. An additional point was awarded if the method of
randomisation or double blinding was described and was
appropriate.
From each trial we extracted the number of patients treat-
ed per group, dosing regimen, study design, and the
number of patients with efficacy and/or safety outcomes.
The denominator was the number of patients randomised
so that results were on an intention-to-treat basis. This
analysis includes all randomised patients regardless of the
completion of diaries, protocol concordance or missing
data. Patients with missing or illegible diary data were as-
sumed to have 0% intercourse success rate. In addition,
this analysis included sexual intercourse attempts that
were unsuccessful for reasons not attributable to sildenafil
i.e. factors other than the erection being insufficiently
hard or long-lasting. RAM extracted the data into tables,
and these were then read and checked by other authors.
For the review, a prior definition of efficacy was a man
with a consistent three-part outcome, consisting of an
erection, sufficiently rigid for penetration, and followed
by successful intercourse. Other efficacy outcomes of in-
terest were the number of men with the highest two re-
sponses on the International Index of Erectile Function
(IIEF) questions 3 and 4, and global evaluations of treat-
ment efficacy by patients [9]. The number of grade 3 or 4
erections (at least hard enough for penetration) and suc-
cessful erections were also noted.
Adverse events were also sought. These were the number
of men with any treatment-related adverse event, the totalBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
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number of men discontinuing, those discontinuing
through lack of efficacy or through adverse events, adverse
events rated severe or serious, and information on partic-
ular adverse events.
Outcomes actually available and chosen were
Efficacy
• Number of men in whom the proportion of successful
attempts at sexual intercourse was more than 60%
• Number of men in whom the proportion of successful
attempts at sexual intercourse was more than 40%
• Number of men reporting that their erections had been
improved on a global question (global A; "Has the treat-
ment you have been taking over the past four weeks im-
proved your erections?").
Erections
• The weighted mean number of weekly erections was cal-
culated.
• The weighted mean success rate was calculated.
• The weighted mean weekly number of successful occa-
sions where intercourse occurred was calculated from
these numbers.
Adverse events
• Treatment-related adverse events
• Severe adverse events
• Serious adverse events
• Dyspepsia
• Headache
• Vasodilation (flushing)
Discontinuations
• All-cause discontinuations
• Discontinuations due to inefficacy
• Discontinuations due to adverse events
A prior intention was to analyse effectiveness and harm
according to dose. Dosing could be fixed, or could be op-
timised where patients took an initial dose of 50 mg, and
then move up to 100 mg or down to 25 mg on subsequent
occasions depending on their individual judgement of the
efficacy or adverse events caused by that dose.
There was no intention of pooling mean data because the
results were not known to have a normal distribution
[10], but rather to find dichotomous data. Relative benefit
and relative risk estimates were calculated with 95% con-
fidence intervals using a fixed effects model [11]. No pool-
ing was done unless there were at least two studies or at
least 200 men in the comparison. The number needed to
treat (NNT) and number needed to harm (NNH), with
confidence intervals, were calculated by the method of
Cook and Sackett [12]. Confidence intervals (95%) for
single samples were calculated for proportions [13]. Het-
erogeneity tests were not used as they have previously
been shown to be unhelpful [13]. Clinical criteria for ho-
mogeneity was defined before analysis and examined
graphically [14]. Publication bias was not assessed using
funnel plots as these tests have been shown to be unhelp-
ful [15,16], and publication bias was not an issue here.
Relative benefit or risk was considered to be statistically
significant when the 95% confidence interval did not in-
clude 1. NNT or NNH values were only calculated when
the relative risk or benefit was statistically significant, and
are reported with the 95% confidence interval. Statistical
significance of any difference between numbers needed to
treat for different doses was assumed if there was no over-
lap of the confidence intervals, and additionally tested us-
ing the z statistic [16]. Calculations were performed using
Microsoft Excel 98 on a Power Macintosh G4.
Results
Twenty-seven clinical trial reports were made available, all
prepared for a marketing authorisation application, and
dated September 1997. Some of these were single dose use
in laboratory setting with penile plethysmography as an
outcome. Others were open extensions of randomised
studies. These were not useful, and 17 were excluded; de-
tails of excluded studies and reasons for exclusions are giv-
en in Additional File 1. There were no details of any
ongoing studies.
Ten studies could be included (study report numbers 101,
102, 103, 106, 355, 356, 359, 361, 363, 364) with 1846
men given sildenafil (25 to 100 mg) and 1131 given pla-
cebo. An additional 277 men were given sildenafil at 5 mg
or 200 mg. Details of trial design for the included studies
is given in Additional File 2. Nine were parallel group and
one had a crossover design, with fixed doses of sildenafil,
or dose-optimised sildenafil, or both, and all had a place-
bo comparator group. Study duration was a minimum of
six weeks and a maximum of six months.
Description of included studies
The number or percentage of men with various efficacy
(more than 60% or 40% success, global rating, number
erections and successful attempts at intercourse)(includ-BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
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ing treatment related adverse events and discontinua-
tions) and adverse event outcomes are shown for
individual trials in Additional File 3. These outcomes were
taken at 12 weeks, or at a time as close to 12 weeks as pos-
sible.
All ten of the included clinical trial reports had a quality
score of 3 (two) or 4 (eight) out of 5. All were randomised
but only two stated how randomisation was achieved. All
stated that they were double blind, and six explained how
blinding was achieved (double-dummy, identical place-
bo). All studies described withdrawals clearly and were
performed on an intention-to-treat basis incorporating
patients with unsuccessful attempts for reasons not asso-
ciated with sildenafil.
For inclusion in a study a man typically had to have a min-
imum six-month history of erectile dysfunction, be 18
years or older, be in a heterosexual relationship for at least
six months and be able to give written consent. There was
typically a long (21 point) list of exclusions that included
anatomical deformities, other sexual disorders, diabetes
with poor control and/or untreated proliferative retinop-
athy, recent (six month) history of heart attack or stroke,
significant cardiovascular disease, active peptic ulceration
or bleeding, use of other treatments for erectile dysfunc-
tion and known history of retinitis pigmentosa. All of the
clinical exclusions were sensible and would form part of
clinical advice regarding advisability of any new treat-
ment. Nine of the ten studies described men as having
erectile dysfunction of organic, mixed and psychogenic
aetiology; a small number of men in the trials also had di-
abetes.
Typically men would attend for a screening visit to record
medical information and to have a physical examination.
Treatments were to be taken as required before anticipated
sexual activity on an outpatient basis over periods up to
12 weeks. No more than one treatment was to be taken on
any one day.
Efficacy was determined using the 15 questions of the IIEF
questionnaire, plus a global efficacy assessment ("Has the
treatment you have been taking over the past four weeks
improved your erections?"), plus a log or erectile function
recording details of erections, their hardness, its duration,
and whether or not erection was maintained long enough
to complete the sexual activity. The main reported out-
comes were responses to IIEF questions 3 ("Over the past
four weeks, when you attempted sexual intercourse, how
often were you able to penetrate your partner?") and ques-
tion 4 ("Over the past four weeks, during sexual inter-
course, how often were you able to maintain your erection
after you had penetrated your partner?").
Adverse events, observed or volunteered, were recorded,
and investigators were to pursue all adverse events. Seri-
ous adverse events were defined as fatal, life-threatening,
permanently disabling, requiring hospital admission,
congenital abnormality, cancer or overdose, or considered
serious enough for immediate reporting.
Results Of meta-analysis
Efficacy
The efficacy results closest to the prior definition of effica-
cy of a man with the consistent three part outcome, con-
sisting of an erection, sufficiently rigid for penetration,
and followed by successful intercourse were the number
of men in whom at least 60% or at least 40% of attempts
at sexual intercourse were successful. The results for at
least 60% of attempts successful are shown in Table 1 and
Figure 1. All doses were significantly better than placebo.
In three studies 48% of men had this outcome with dose
optimisation compared with 11% with placebo; the
number needed to treat was 2.7 (95% CI 2.3 to 3.2).
Dose-optimisation produced a significantly lower (better)
NNT than a 25 mg fixed dose.
Figure 1
Each symbol represents the percentage of men with at least
60% success with viagra or placebo. Size of the symbol is
proportional to the size of the studyBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
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The results for at least 40% success are shown in Table 2
and Figure 2. All doses were significantly better than pla-
cebo. In three studies 60% of men had this outcome with
dose optimisation compared with 19% with placebo; the
number needed to treat was 2.4 (95% CI 2.1 to 2.9).
Dose-optimisation produced a significantly lower (better)
NNT than a 25 mg fixed dose.
More men responded positively to the global question
about improved erections with sildenafil than with place-
bo (Table 3, Figure 3). All doses were significantly better
than placebo. In five studies 79% of men responded pos-
itively with dose optimisation compared with 21% with
placebo; the number needed to treat was 1.7 (1.6 to 1.9).
Dose-optimisation produced a significantly lower (better)
NNT than 25 mg and 50 mg fixed doses.
Responses on IIEF questions 3 and 4 were not given as
proportions, but as means. Pooling of mean data was not
attempted.
Erections
The weighted mean number of erections per week and
successful erections in which intercourse took place with
different doses of sildenafil and with placebo are shown
in Figure 4. With placebo erections with successful inter-
course occurred on average less often than once every five
weeks. With dose optimised sildenafil they occurred more
often than once a week. Dose optimisation produced
more successful erections, and more erections in total,
than did 50 mg or 100 mg fixed dose sildenafil.
Adverse events
Treatment related adverse events are shown in Table 4.
They occurred more frequently with sildenafil than with
placebo for all doses. Dose optimisation produced 30% of
patients with adverse events compared with 11% with pla-
cebo; the number needed to harm was 5.4 (4.3 to 7.3).
This was significantly greater (better) than 100 mg and
200 mg fixed doses.
Serious adverse events were no more frequent with silde-
nafil than placebo at any dose (Additional File 4). Adverse
Table 1: At least 60% of attempts at sexual intercourse successful
Number (%) with outcome
Dosing (mg) Number of trials Sildenafil Placebo Relative benefit 
(95% CI)
NNT (95% CI)
25 3 88/312 (28) 43/426 (10) 3.0 (2.1 to 4.2) 5.5 (4.2 to 8.1)
50 5 216/511 (42) 62/607 (10) 4.3 (3.3 to 5.6) 3.1 (2.7 to 3.7)
100 5 223/506 (44) 62/607 (10) 4.4 (3.4 to 5.8) 3.0 (2.6 to 3.5)
200 2 93/191 (49) 19/181 (10) 4.5 (2.9 to 7.1) 2.6 (2.2 to 3.4)
Dose optimised 3 183/379 (48) 43/376 (11) 4.2 (3.1 to 5.6) 2.7 (2.3 to 3.2)
Table 2: At least 40% of attempts at sexual intercourse successful
Number (%) with outcome
Dosing (mg) Number of trials Sildenafil Placebo Relative benefit 
(95% CI)
NNT (95% CI)
25 3 122/312 (39) 70/426 (16) 2.6 (2.0 to 3.3) 4.4 (3.4 to 6.2)
50 5 269/511 (53) 102/607 (17) 3.3 (2.7 to 4.0) 2.8 (2.4 to 3.3)
100 5 272/506 (54) 102/607 (17) 3.3 (2.7 to 4.1) 2.7 (2.4 to 3.2)
200 2 106/191 (55) 32/181 (18) 3.1 (2.2 to 4.3) 2.6 (2.1 to 3.5)
Dose optimised 3 227/379 (60) 70/376 (19) 3.2 (2.6 to 4.0) 2.4 (2.1 to 2.9)BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
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events described as severe occurred more frequently than
placebo with 100 mg and 200 mg fixed doses, but not
with dose optimisation or 25 mg or 50 mg fixed doses
(Additional File 5).
Consistent information was available from clinical trial
reports for three specific adverse events – dyspepsia, head-
ache and vasodilation. The incidence of these all increased
with dose (Table 5), resulting in lower (worse) values for
NNH. For dyspepsia, dose optimisation produced signifi-
Table 3: Positive response to global question about improved erections
Number (%) with outcome
Dosing (mg) Number of trials Sildenafil Placebo Relative benefit 
(95% CI)
NNT (95% CI)
25 3 192/312 (62) 114/426 (27) 2.3 (1.9 to 2.8) 2.8 (2.4 to 3.5)
50 5 378/511 (74) 153/607 (25) 3.0 (2.6 to 3.5) 2.1 (1.9 to 2.3)
100 5 415/506 (82) 153/607 (25) 3.3 (2.9 to 3.8) 1.8 (1.6 to 1.9)
200 2 152/191 (80) 39/181 (22) 3.7 (2.8 to 5.0) 1.7 (1.5 to 2.0)
Dose optimised 5 411/517 (79) 111/524 (21) 3.8 (3.2 to 4.5) 1.7 (1.6 to 1.9)
Figure 2
Each symbol represents the percentage of men with at least
40% success with viagra or placebo. Size of the symbol is
proportional to the size of the study
Figure 3
Each symbol represents the percentage of men with
improved erections with viagra or placebo using the global
score. Size of the symbol is proportional to the size of the
studyBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
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cantly higher (better) NNH values than did 50 mg, 100
mg or 200 mg. For headache, dose optimisation produced
significantly higher NNH values than 100 mg and 200
mg. For vasodilation, dose optimisation produced similar
NNH values to all fixed doses.
Discontinuations
All cause discontinuations are shown in Table 6. All cause
discontinuations were significantly lower with sildenafil
at 50 mg and 100 mg fixed doses and with dose optimisa-
tion.
Table 4: Treatment related adverse events
Number (%) with outcome
Dosing (mg) Number of trials Sildenafil Placebo Relative risk (95% 
CI)
NNH (95% CI)
25 3 71/312 (23) 33/426 (8) 2.8 (1.9 to 4.2) 6.7 (4.9 to 10)
50 5 190/508 (37) 59/607 (10) 3.7 (2.8 to 4.8) 3.6 (3.1 to 4.4)
100 5 260/506 (51) 59/607 (10) 5.0 (3.9 to 6.5) 2.4 (2.2 to 2.7)
200 2 137/191 (72) 26/181 (14) 5.0 (3.5 to 7.2) 1.7 (1.5 to 2.0)
Dose optimised 5 155/517 (30) 60/524 (11) 2.6 (2.0 to 3.4) 5.4 (4.3 to 7.3)
Figure 4
Mean number of erections a week (blue), and erections resulting in successful intercourse (red) with placebo and different
doses and dosing schedules of sildenafilBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
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Discontinuations because of lack of efficacy were signifi-
cantly lower with sildenafil at 50 mg and 100 mg fixed
doses and with dose optimisation (Additional File 6).
Discontinuations due to adverse effects were not different
between sildenafil at any dose and placebo (Additional
File 7).
Discussion
This review demonstrated that considerable amounts of
useful information are available in clinical trial reports
submitted for marketing authorisation (licensing). That
information adequately describes research methods used,
though could be improved, perhaps using the updated
CONSORT criteria [17]. If these guidelines are becoming
necessary for publication of randomised trials in our ma-
jor medical journals, then they should be minimum crite-
ria for clinical trials reports required by licensing
authorities. We did not check the reports against each
CONSORT criterion because the reports were from 1997
soon after the publication of the original CONSORT state-
ment [17].
Despite scores of 3 or 4 out of five on a commonly-used
quality score, and acknowledging that scores like this are
not associated with bias [18,19], the areas where the clin-
Table 5: Specific adverse events (treatment related) in comparisons with placebo
Number (%) with outcome
Dosing (mg) Number of 
trials
Adverse event Sildenafil Placebo Relative risk (95% CI) NNH (95% CI)
25 3 Dyspepsia 4/312 (1.2) 1/426 (0.2) 4.4 (0.6 to 34)
Headache 31/312 (10) 14/426 (3.2) 3.1 (1.6 to 6.1) 15 (9.6 to 34)
Vasodilation 30/312 (9.6) 4/426 (1.0) 11 (3.8 to 29) 12 (8.3 to 19)
50 5 Dyspepsia 24/511 (4.7) 4/607 (0.7) 6.4 (2.4 to 17) 24 (17 to 47)
Headache 77/511 (15) 21/607 (0.3) 4.5 (2.8 to 7.3) 8.6 (6.6 to 12)
Vasodilation 94/511 (18) 11/607 (1.8) 9.7 (5.4 to 18) 6.0 (5.0 to 7.7)
100 5 Dyspepsia 60/506 (12) 4/607 (0.7) 15 (5.8 to 40) 8.9 (7.1 to 12)
Headache 115/506 (23) 21/607 (0.3) 6.8 (4.3 to 11) 5.2 (4.3 to 6.5)
Vasodilation 90/506 (17) 11/607 (1.8) 9.2 (5.0 to 17) 6.3 (5.1 to 8.0)
200 2 Dyspepsia 35/191 (18) 3/181 (1.7) 11 (3.5 to 35) 6.0 (4.5 to 9.2)
Headache 62/191 (32) 7/181 (3.9) 8.4 (4.0 to 18) 3.5 (2.8 to 4.7)
Vasodilation 43/191 (22) 7/181 (3.9) 5.9 (2.7 to 13) 5.4 (4.0 to 8.3)
Dose optimised 5 Dyspepsia 24/517 (4.6) 7/524 (1.3) 3.4 (1.5 to 7.9) 31 (19 to 82)
Headache 63/517 (12) 10/524 (1.9) 6.3 (3.2 to 12) 9.8 (7.5 to 14)
Vasodilation 65/517 (13) 4/524 (0.8) 16 (6.0 to 44) 8.5 (6.7 to 11)
Table 6: All cause discontinuations
Number (%) with outcome
Dosing (mg) Number of trials Sildenafil Placebo Relative risk (95% 
CI)
NNH (95% CI)
25 3 32/312 (10) 63/426 (15) 0.75 (0.50 to 1.11)
50 5 36/508 (7) 86/607 (14) 0.52 (0.36 to 0.76) -14 (-9 to -28)
100 5 47/506 (9) 86/607 (14) 0.67 (0.47 to 0.95) -20 (-12 to -89)
200 2 18/191 (9) 23/181 (13) 0.76 (0.43 to 1.35)
Dose optimised 5 52/517 (10) 104/524 (20) 0.50 (0.37 to 0.67) -10 (-7 to -18)BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
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ical trials reports were weak were important ones. Only
two reports stated how the randomisation sequence was
generated. No report adequately described allocation con-
cealment, though several mentioned sealed envelopes. No
report described the implementation of the allocation se-
quence. Only two reports described how double blinding
was achieved.
In other areas, reporting was good. Participants, and in-
clusion and exclusion criteria were explicit, as was a de-
scription of the intervention. Patient flow (though
without diagrams) was thoroughly described, together
with reasons for withdrawal. Baseline information on par-
ticipants, numbers analysed and methods used were all
well described, both for efficacy and adverse events. One
criticism, outside CONSORT, was the use of mean scores
for results of IIEF questions. Mean scores are of little value,
especially when there may not be a normal distribution
when they can be misleading [10]. Better would be the
number or proportion of men achieving good or excellent
outcomes.
Clinical trial reports were a good source of information,
and with minor changes would become an excellent
source of information for meta-analysis. For sildenafil in
erectile dysfunction these reports allowed interesting con-
clusions to be drawn from a homogeneous population of
men with similar aetiologies, but excluding those with
erectile dysfunction following spinal cord trauma, with
diabetes, or following treatment for prostate cancer. Al-
though two small studies on spinal cord trauma and one
on diabetes were available in the full review, much more
information on men with erectile dysfunction of particu-
lar aetiology has become available since 1997 [19], [19],
[20], [21], [22], [23].
Efficacy was available in a number of formats in addition
to mean responses to IIEF scores 3 and 4. The number of
men in whom sildenafil was successful (erections hard
enough for penetration, and resulting in intercourse)
more than 60% of the time, and more than 40% of the
time was available, and chosen by us for evaluation. Cut
points every 20% from 0% to 100% were also available.
Figure 5
Mean percentage of men achieving the outcomes of more than 60% success (blue) more than 40% success (red) and improved
erections on the global question (green) with placebo and different doses and dosing schedules of sildenafilBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
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The number of men responding positively to the global
question on improved erections was also available. Clear-
ly there is a gradation here from outcomes that are less
easy to achieve to those that are easier to fulfil. A greater
proportion of men achieved the easier than harder out-
come for all doses (Figure 5). Numbers needed to treat
and the proportion of patients achieving the outcome
could easily be calculated.
Adverse events were also well described, and presented in
a number of formats, from the number of men with any
treatment related adverse event, through the number with
severe or serious adverse events, particular adverse events,
and discontinuations. From these it was possible to calcu-
late numbers needed to harm and the proportion of pa-
tients for each outcome.
The ability to perform these calculations with information
pooled from 10 studies was informative. Firstly, it sup-
ported the optimised dosing regimen for sildenafil. Opti-
mised dosing produced efficacy equivalent to the highest
fixed dose, and harm equivalent to the lowest fixed dose.
Figure 6 shows the effects on the two broadest efficacy and
harm outcomes, global response about improved erec-
tions and treatment related adverse effects. Figure 7 shows
the NNTs and NNHs for three efficacy outcomes, three
harm outcomes and three discontinuation outcomes. Op-
timised dosing was better than fixed dosing.
It is also germane to enquire whether results obtained
from clinical trial reports of the earliest studies are borne
out in later reviews. A review of 20 trials comparing silde-
nafil with placebo with about 4,000 men included both
published and unpublished information, and supple-
mented by the manufacturer where appropriate, arrived at
broadly similar results [24]. Only seven of the references
to trials in that review were dated 1997 or before (mostly
as abstracts), and would have been available at the time of
marketing approval. Though combining all doses of silde-
nafil from 5 mg to 200 mg and dose escalation together in
a comparison with placebo, the result for global efficacy
Figure 6
Mean percentage of men with improved erections on a global scale (blue), and reporting treatment related adverse effects
(red) with placebo and different doses and dosing schedules of sildenafilBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/6
Page 11 of 12
(page number not for citation purposes)
yielded an NNT of 2, the same as is found in this review
for all doses higher than 25 mg (Table 3).
This investigation of the evidential properties of clinical
trial reports of sildenafil for treatment of erectile dysfunc-
tion indicates that, in this instance, reports could have
been used for systematic review at the time of product
launch. With little additional effort the clinical trial re-
ports could have fulfilled CONSORT guidelines for the re-
porting of randomised controlled trials. Making clinical
trial reports publicly available at the time of product
launch, perhaps through the Internet, would make their
introduction evidence-based, as well as allowing health-
care services to plan ahead more effectively. This would
benefit commercial organisations by maximising the up-
take of effective new technology, and may accelerate dis-
continuation of less effective, or less safe, older
technology.
Conclusions
Clinical trial reports presented for marketing approval did
provide the basis for a systematic review at the time of
launch for sildenafil for the treatment of male erectile dys-
function. To our knowledge these documents were not
publicly available at the time. Were clinical trials reports
used for marketing approval publicly available, then re-
view and meta-analysis would allow an early appreciation
of benefits or pitfalls§for patients and healthcare systems.
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